Metformin Brown & Burk Uk (Metformin Hydrochloride)

Metformin primarily activates AMP‑activated protein kinase (AMPK) in the liver, which suppresses gluconeogenesis and decreases glucose output. It also enhances peripheral glucose uptake in muscle and adipose tissue, improves insulin sensitivity, and modestly reduces intestinal glucose absorption, collectively contributing to lower blood glucose levels.

The appropriate dose of Metformin Brown & Burk UK is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycemic targets, and tolerability. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose without medical guidance.

Metformin is classified as pregnancy category unknown, and its safety in pregnancy or lactation is not fully established. It should only be used during pregnancy or while breastfeeding if the potential benefits outweigh the possible risks, and this decision must be made by the treating physician.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metformin belongs to the biguanide class and is often first‑line therapy for type 2 diabetes because of its efficacy, low risk of hypoglycemia, and favorable impact on weight. Compared with sulfonylureas, it does not cause insulin spikes, and unlike insulin, it is administered orally. It may be combined with other agents for additional glucose control.

Metformin Brown & Burk UK should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not crush or chew the tablets unless specifically instructed.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or conditions that predispose to hypoxia. Other serious concerns include severe skin reactions such as Stevens‑Johnson syndrome and significant vitamin B12 deficiency with long‑term use.

Metformin is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with known hypersensitivity to metformin or other biguanides. Caution is also advised for patients with liver disease, heart failure, or a history of alcohol abuse.